AVITA Medical Welcomes Support for RECELL® in Burns in Australia
AVITA Medical (NASDAQ: RCEL) announced that Australia’s Medical Services Advisory Committee (MSAC) recommended amendments to the Medicare Benefits Schedule to include autologous skin cell suspension (ASCS) prepared with RECELL for severe acute burn wounds in adults and children.
MSAC concluded RECELL is as safe and effective as traditional autologous skin grafting and noted benefits including donor site sparing, reduced need for additional grafting, shorter hospital stays, less pain, and minimized scarring. Recommended uses include adults with ≥20% TBSA, pediatrics with ≥10% TBSA, and whole-of-face closure.
AVITA Medical (NASDAQ: RCEL) ha annunciato che il Medical Services Advisory Committee australiano (MSAC) ha raccomandato modifiche al Medicare Benefits Schedule per includere la sospensione di cellule cutanee autologhe (ASCS) preparata con RECELL per ustioni gravi in adulti e bambini.
MSAC ha concluso che RECELL è sicuro ed efficace quanto la tradizionale innesto cutaneo autologo e ha evidenziato benefici quali evitare il sito donatore, ridotta necessità di innesti aggiuntivi, minor durata del ricovero, minore dolore e cicatrizzazione minimizzata. Gli usi raccomandati includono adulti con ≥20% della superficie corporea ustionata (TBSA), pazienti pediatrici con ≥10% TBSA e chiusura dell'intera faccia.
AVITA Medical (NASDAQ: RCEL) anunció que el Comité Asesor de Servicios Médicos de Australia (MSAC) recomendó enmendar el Medicare Benefits Schedule para incluir la suspensión de células cutáneas autólogas (ASCS) preparada con RECELL para heridas graves por quemaduras en adultos y niños.
MSAC concluyó que RECELL es tan seguro y eficaz como el injerto de piel autólogo tradicional y señaló beneficios como ahorro de la zona donante, menor necesidad de injertos adicionales, estancias hospitalarias más cortas, menos dolor y cicatrización minimizada. Usos recomendados incluyen adultos con ≥20% de TBSA, pediatría con ≥10% TBSA y cierre de toda la cara.
AVITA Medical (나스닥: RCEL)은 호주 의료 서비스 자문위원회(MSAC)가 성인 및 소아의 중증 화상 상처에 대해 RECELL로 준비된 자가 피부 세포 현탁액(ASCS)을 메디케어 혜택 일정에 포함하도록 개정안을 권고했다고 발표했습니다.
MSAC는 RECELL이 전통적 자가 피부 이식과 안전하고 효과적이라고 결론지었으며, 기증 부위 절감, 추가 이식 필요 감소, 입원 기간 단축, 통증 감소 및 흉터 최소화 등의 이점을 지적했습니다. 권장 사용 범위에는 성인의 TBSA ≥20%, 소아의 TBSA ≥10%, 그리고 얼굴 전체 폐쇄가 포함됩니다.
AVITA Medical (NASDAQ : RCEL) a annoncé que le Comité consultatif des services médicaux d’Australie (MSAC) a recommandé des amendements au Medicare Benefits Schedule pour inclure la suspension de cellules cutanées autologues (ASCS) préparée avec RECELL pour les brûlures graves chez l’adulte et l’enfant.
Le MSAC a conclu que RECELL est sécuritaire et efficace équivalent à la greffe cutanée autologue traditionnelle et a noté des bénéfices tels que l’épargne du site donneur, une réduction des greffes supplémentaires, des séjours hospitaliers plus courts, moins de douleur et des cicatrices minimisées. Les utilisations recommandées incluent les adultes avec ≥20% de TBSA, la pediatrie avec ≥10% TBSA et la fermeture de l’ensemble du visage.
AVITA Medical (NASDAQ: RCEL) gab bekannt, dass das australische Medical Services Advisory Committee (MSAC) Änderungen am Medicare Benefits Schedule empfiehlt, um autologe Hautzellensuspension (ASCS), die mit RECELL hergestellt wird, für schwere akute Verbrennungen bei Erwachsenen und Kindern einzubeziehen.
MSAC kam zu dem Schluss, dass RECELL so sicher und wirksam ist wie traditionelle autologe Hauttransplantationen und hob Vorteile wie Spenderstelle eingespart, geringerer Bedarf an weiteren Transplantaten, kürzere Krankenhausaufenthalte, weniger Schmerzen und minimierte Narbenbildung. Empfohlene Anwendungen umfassen Erwachsene mit ≥20% TBSA, Pädiatrie mit ≥10% TBSA und die vollständige Gesichtsabdeckung.
AVITA Medical (مدرجة في NASDAQ: RCEL) أعلنت أن اللجنة الاستشارية للخدمات الطبية في أستراليا (MSAC) أوصت بإجراء تعديلات على جدول مزايا ميديكير لتضمين تعليق الخلايا الجلدية الذاتية التحضير (ASCS) المحضّرة باستخدام RECELL لالتئام جروح الحروق الشديد لدى البالغين والأطفال.
خلص MSAC إلى أن RECELL آمن وفعّال بقدر التطعيمات الجلدية الذاتية التقليدية وأنه يوفر فوائد من بينها توفير موقع المتبرع، وتقليل الحاجة إلى زراعة إضافية، و< b>قِصر الإقامة في المستشفى، وألم أقل وتندّب أقل. تشمل الاستخدامات الموصى بها البالغين بــ≥20% TBSA، والمرضى الأطفال بــ≥10% TBSA، وإغلاق كامل لوجه.
AVITA Medical（纳斯达克股票代码：RCEL）宣布，澳大利亚的医疗服务咨询委员会（MSAC）建议修订《医疗保险福利计划》（Medicare Benefits Schedule）以将用RECELL制备的自体皮肤细胞悬浮液（ASCS）纳入，用于成人和儿童的重度烧伤创面。
MSAC 认为 RECELL 与传统自体皮肤移植同样安全有效，并指出其带来的好处包括省去供体部位、减少需要额外移植、住院时间缩短、疼痛更小、瘢痕最小化。推荐使用包括≥20% TBSA 的成人、≥10% TBSA 的儿科患者，以及全脸闭合。
- MSAC recommended MBS amendment to include RECELL
- MSAC found RECELL as safe and effective as traditional grafting
- Donor site sparing and reduced need for additional grafting
- Shorter hospital stays and reduced patient pain
- Specified eligible populations: adults ≥20% TBSA, pediatrics ≥10% TBSA, whole-of-face
- None.
Insights
MSAC recommending MBS listing for RECELL is a material, positive reimbursement and clinical endorsement for severe burn care.
MSAC concluded RECELL is as safe and effective as traditional autologous grafting while reducing donor-site morbidity and the need for additional grafts. The recommendation to amend the Medicare Benefits Schedule creates a clear pathway for funded access in Australia for adults with burns ≥
The program’s business impact depends on uptake by burn centers, procedural coding, and time to MBS implementation; these remain the key dependencies and sources of execution risk. Watch for formal MBS listing details and timing around
- Australia’s Medical Services Advisory Committee (MSAC) recognizes RECELL® as safe and effective, with benefits in healing, donor site sparing, and reduced hospital stays
VALENCIA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced that Australia’s Medical Services Advisory Committee (“MSAC”) has recommended amendments to the Medicare Benefits Schedule (“MBS”) to include the use of autologous skin cell suspension (“ASCS”) prepared with RECELL for the treatment of severe acute burn wounds in adults and children.
“MSAC’s position is a powerful endorsement of RECELL’s clinical impact and the difference it makes in patients’ lives,” said Katie Bush, PhD, Senior Vice President, Scientific & Medical Affairs. “It reflects growing confidence in RECELL as a transformative approach in burn care and represents our shared goals of improving outcomes for patients and supporting clinicians with innovative treatment options.”
MSAC concluded that RECELL is as safe and effective as traditional autologous skin grafting, while providing superior outcomes in donor site sparing and reducing the need for additional grafting procedures. MSAC further acknowledged that RECELL can shorten hospital stays, ease patient pain, and minimize scarring.
Severe burns often require surgery to close the wound, which usually involves taking healthy skin from another part of the body and grafting it onto the burn. This process can be painful, leaves lasting scars at the donor site, and often requires long hospital stays.
RECELL works differently. By taking a very small piece of the patient’s own healthy skin, doctors can prepare a suspension of skin cells that is sprayed onto the wound. This can:
- Reduce the need for large skin grafts, lowering pain and scarring at donor sites
- Shorten hospital stays, helping patients recover faster and return to daily life sooner
The MSAC recommendation supports the use of RECELL for:
- Adult patients with burns covering ≥
20% of total body surface area (“TBSA”) - Pediatric patients with burns covering ≥
10% TBSA - Whole-of-face burn wound closure
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.
To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “can,” could,” “usually,” “will,” “would,” and similar words or expressions, and the use of future dates. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation: failure to obtain and/or maintain regulatory approvals and comply with applicable regulations; market reaction to growth or product initiatives; market penetration of our products; changes in the legal or regulatory environments; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. Any forward-looking statements made herein are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
What did MSAC recommend for RECELL on October 28, 2025 for AVITA Medical (RCEL)?
Which burn patients does the MSAC recommendation cover for RECELL (RCEL)?
How did MSAC assess RECELL compared with traditional skin grafting for RCEL?
What clinical benefits did MSAC cite for RECELL in the MSAC recommendation for RCEL?
Will the MSAC recommendation affect Medicare billing for RECELL (RCEL) in Australia?
